NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...
EVEREST MED (01952.HK) announced that, in relation to the exclusive licensing and collaboration agreement signed with Travere ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX). TipRanks has entered a new arena in the investing ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Recently published Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, ...
Novo Nordisk today unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig (Mim8) subcutaneous prophylaxis in children, ...
Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a global leader in precision biomarker science, today ...
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...
With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...
View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results